Marker Therapeutics
MRKRClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($4.18M) ($2.35M) ($11.80M) ($2.84M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($0.95M) ($1.02M) ($4.18M) ($1.23M)
Operating Income / (Loss)
($4.26M) ($2.14M) ($12.89M) ($4.07M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
$0.13M $0.14M $0.59M $0.13M
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
— — — —
Income Tax Provision / (Benefit)
— — ($0.02M) —
NET INCOME / (NET LOSS)
($4.02M) ($2.00M) ($12.16M) ($3.18M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$10.5M$17.6M$16.1M$14.9M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$10.5M$17.6M$16.1M$14.9M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$4.3M$4.1M$0.7M$0.4M
Total Current Assets
$14.8M$21.7M$19.1M$17.4M
Property, Plant and Equipment, Net
// --// --// --// --
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$14.8M$21.7M$19.1M$17.4M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$1.7M$1.0M$0.8M$1.5M
Accrued Expenses & Clinical Liabilities
$0.1M$0.0M$0.1M$0.1M
Total Current Liabilities
$4.3M$3.3M$2.3M$3.6M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$0.0M$0.0M$0.0M$0.0M
Total Liabilities Block
$4.3M$3.3M$2.3M$3.6M
Total Stockholders' Equity
$10.5M$18.4M$16.8M$13.8M
TOTAL LIABILITIES & EQUITY
$14.8M$21.7M$19.1M$17.4M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
3.45x 6.50x 8.39x 4.79x
R&D Expenditure Flow
$7.3M$9.7M$11.8M$2.8M
Net Income / (Loss)
($4.02M) ($2.00M) ($12.16M) ($3.18M)
Depreciation & Amortization
— — — —
Stock-Based Compensation
$0.39M $0.43M $0.54M $0.18M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
— — — —
Change in Payables & Clinical Accruals
$0.51M ($0.09M) ($0.45M) $0.61M
Other Operating Source / (Use) Changes
($4.27M) ($8.45M) $0.07M $0.98M
Net Cash from Operating Activities
($7.38M) ($10.11M) ($12.01M) ($1.40M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
— — — —
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
— — — —
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— $9.86M $9.86M —
Net Cash from Financing Activities
$0.00M $9.86M $9.86M —
NET CONSOLIDATED CHANGE IN CASH
— — — —
Clinical Trials Registry
Registry ID
Phase / Asset
Status